Skip to content
Peptigraph home

How to Inject PT-141: Sites, Syringes and Steps

Where to inject PT-141, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureMelanocortin agonistUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor. If you were prescribed a PT-141 pen, follow the pen's own instructions instead.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for PT-141 in studies: not reported in study abstracts (PubMed search, 2 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

The approved form is a single-dose autoinjector, not a vial

Vyleesi is supplied as 1.75 mg in 0.3 mL in a single-dose autoinjector, so the label has no reconstitution step.[7]

The label describes self-administration through a prefilled pen and asks users to look at the solution first and discard it if cloudy, discoloured or containing particles.[7]

The strength works out to 1.75 / 0.3 = 5.83 mg per mL.

Calculated from mg 1.75; m L 0.3; U100 units per m L 100. Formula: 1.75 / 0.3 = 5.83 mg/mL; 0.3 x 100 = 30 units

Site, exposure and timing in the label

The label names the abdomen or thigh, and the pharmacokinetics section found no meaningful difference in exposure between the two.[7]

Absolute bioavailability by the subcutaneous route was about 100%.[7]

The terminal half-life after a single injection is about 2.7 hours, with a range of 1.9 to 4.0 hours.[7]

The label says doses are not to be given more than once within 24 hours, and that more than 8 doses per month is not recommended.[7]

Population limits and effects people notice

The label limits use to premenopausal women with acquired generalised HSDD, and says it is not indicated in postmenopausal women, in men, or to enhance sexual performance.[7]

The label lists uncontrolled hypertension and known cardiovascular disease as contraindications.[7]

Measured effects peaked 2 to 4 hours after a dose, with maximal rises of 6 mmHg systolic and 3 mmHg diastolic.[7]

Nausea was reported by 40% of patients, 13% needed anti-emetic therapy, and 8% stopped early.[7]

Storage and the research-vial question

Storage is at or below 25°C, away from light, and never frozen.[7]

An FDA warning letter lists 'PT-141' among products it calls unapproved new drugs under section 505(a) of the FD&C Act.[8]

Common questions

Where do you inject PT-141?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for PT-141?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is PT-141 injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

Where do you inject PT-141 (Vyleesi)?

The label says the abdomen or thigh, using the single-dose autoinjector.[7]

Does the injection site change how much PT-141 reaches the blood?

Not significantly, according to the label's abdomen versus thigh comparison.[7]

Can men use Vyleesi?

The label states it is not indicated in men.[7]

More on PT-141

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] (114 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND randomized controlled trial[pt] (14 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab]) AND (erectile[tiab] OR men[tiab]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7VYLEESI prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  8. 8Official web pageOfficial web page · web page

Found an error? Report a correction.